L‐type calcium channel blockers and Parkinson disease in Denmark
Identifieur interne : 000651 ( Main/Exploration ); précédent : 000650; suivant : 000652L‐type calcium channel blockers and Parkinson disease in Denmark
Auteurs : Beate Ritz [États-Unis] ; Shannon L. Rhodes [États-Unis] ; Lei Qian [États-Unis] ; Eva Schernhammer [États-Unis] ; J Rgen H. Olsen [Danemark] ; S Ren Friis [Danemark]Source :
- Annals of Neurology [ 0364-5134 ] ; 2010-05.
Abstract
Objective: This study was undertaken to investigate L‐type calcium channel blockers of the dihydropyridine class for association with Parkinson disease (PD), because some of these drugs traverse the blood–brain barrier, are potentially neuroprotective, and have previously been evaluated for impact on PD risk. Methods: We identified 1,931 patients with a first‐time diagnosis for PD between 2001 and 2006 as reported in the Danish national hospital/outpatient database and density matched them by birth year and sex to 9,651 controls from the population register. The index date for cases and their corresponding controls was advanced to the date of first recorded prescription for anti‐Parkinson drugs, if prior to first PD diagnosis in the hospital records. Prescriptions were determined from the national pharmacy database. In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before index date/PD diagnosis. Results: Employing logistic regression analysis adjusting for age, sex, diagnosis of chronic pulmonary obstructive disorder, and Charlson comorbidity score, we found that subjects prescribed dihydropyridines (excludes amlodipine) between 1995 and 2 years prior to the index date were less likely to develop PD (odds ratio, 0.73; 95% confidence interval, 0.54–0.97); this 27% risk reduction did not differ with length or intensity of use. Risk estimates were close to null for the peripherally acting drug amlodipine and for other antihypertensive medications. Interpretation: Our data suggest a potential neuroprotective role for centrally acting L‐type calcium channel blockers of the dihydropyridine class in PD that should be further investigated in studies that can distinguish between types of L‐type channel blockers. ANN NEUROL 2010;67:600–606
Url:
DOI: 10.1002/ana.21937
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">L‐type calcium channel blockers and Parkinson disease in Denmark</title><author><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name></author><author><name sortKey="Rhodes, Shannon L" sort="Rhodes, Shannon L" uniqKey="Rhodes S" first="Shannon L." last="Rhodes">Shannon L. Rhodes</name></author><author><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name></author><author><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name></author><author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name></author><author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E50818402073257C7CC6666A087EFFC1474C47B7</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/ana.21937</idno><idno type="url">https://api.istex.fr/document/E50818402073257C7CC6666A087EFFC1474C47B7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000436</idno><idno type="wicri:Area/Main/Curation">000377</idno><idno type="wicri:Area/Main/Exploration">000651</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">L‐type calcium channel blockers and Parkinson disease in Denmark</title><author><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Epidemiology, University of California at Los Angeles School of Public Health, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Rhodes, Shannon L" sort="Rhodes, Shannon L" uniqKey="Rhodes S" first="Shannon L." last="Rhodes">Shannon L. Rhodes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Epidemiology, University of California at Los Angeles School of Public Health, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Biostatistics, University of California at Los Angeles School of Public Health, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-05">2010-05</date><biblScope unit="volume">67</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="600">600</biblScope><biblScope unit="page" to="606">606</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">E50818402073257C7CC6666A087EFFC1474C47B7</idno><idno type="DOI">10.1002/ana.21937</idno><idno type="ArticleID">ANA21937</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: This study was undertaken to investigate L‐type calcium channel blockers of the dihydropyridine class for association with Parkinson disease (PD), because some of these drugs traverse the blood–brain barrier, are potentially neuroprotective, and have previously been evaluated for impact on PD risk. Methods: We identified 1,931 patients with a first‐time diagnosis for PD between 2001 and 2006 as reported in the Danish national hospital/outpatient database and density matched them by birth year and sex to 9,651 controls from the population register. The index date for cases and their corresponding controls was advanced to the date of first recorded prescription for anti‐Parkinson drugs, if prior to first PD diagnosis in the hospital records. Prescriptions were determined from the national pharmacy database. In our primary analyses, we excluded all calcium channel blocker prescriptions 2 years before index date/PD diagnosis. Results: Employing logistic regression analysis adjusting for age, sex, diagnosis of chronic pulmonary obstructive disorder, and Charlson comorbidity score, we found that subjects prescribed dihydropyridines (excludes amlodipine) between 1995 and 2 years prior to the index date were less likely to develop PD (odds ratio, 0.73; 95% confidence interval, 0.54–0.97); this 27% risk reduction did not differ with length or intensity of use. Risk estimates were close to null for the peripherally acting drug amlodipine and for other antihypertensive medications. Interpretation: Our data suggest a potential neuroprotective role for centrally acting L‐type calcium channel blockers of the dihydropyridine class in PD that should be further investigated in studies that can distinguish between types of L‐type channel blockers. ANN NEUROL 2010;67:600–606</div></front></TEI><affiliations><list><country><li>Danemark</li><li>États-Unis</li></country><region><li>Californie</li><li>Hovedstaden</li><li>Massachusetts</li></region><settlement><li>Copenhague</li></settlement></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Ritz, Beate" sort="Ritz, Beate" uniqKey="Ritz B" first="Beate" last="Ritz">Beate Ritz</name></region><name sortKey="Qian, Lei" sort="Qian, Lei" uniqKey="Qian L" first="Lei" last="Qian">Lei Qian</name><name sortKey="Rhodes, Shannon L" sort="Rhodes, Shannon L" uniqKey="Rhodes S" first="Shannon L." last="Rhodes">Shannon L. Rhodes</name><name sortKey="Schernhammer, Eva" sort="Schernhammer, Eva" uniqKey="Schernhammer E" first="Eva" last="Schernhammer">Eva Schernhammer</name></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Olsen, J Rgen H" sort="Olsen, J Rgen H" uniqKey="Olsen J" first="J Rgen H." last="Olsen">J Rgen H. Olsen</name></region><name sortKey="Friis, S Ren" sort="Friis, S Ren" uniqKey="Friis S" first="S Ren" last="Friis">S Ren Friis</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E50818402073257C7CC6666A087EFFC1474C47B7
|texte= L‐type calcium channel blockers and Parkinson disease in Denmark
}}
| This area was generated with Dilib version V0.6.23. |  |